Clinical trials
Gastric clinical trials
Below are recruiting gastric clinical trials, each written for real people, not researchers. We’re tracking 850 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06464926Recruiting
Electrical stimulation for chronic nausea and vomiting
This study tests a device that sends mild electrical pulses to your stomach to help with chronic nausea and vomiting. It is for people who have had nausea for over 6 months, have normal stomach emptying, and have not found relief from standard medications.
Scottsdale, ArizonaAges 18 years+ - NCT06461910RecruitingPhase 2
Immunotherapy, thymalfasin, and chemo before surgery for stomach cancer
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Birmingham, AlabamaAges 18 years+ - NCT06408220Recruiting
Stomach cancer risk check for minority groups
This study checks if you are at high risk for stomach cancer. You will give blood samples and have a stomach exam (endoscopy) to look for early signs.
Duarte, CaliforniaAges 40–80 - NCT06417892Recruiting
Fruquintinib combo with or without immunotherapy for stomach cancer
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06391749Enrolling by invitation
Blood test for multiple cancers in people with symptoms
This trial tests a new blood test (SPOT-MAS) that looks for signs of multiple cancers in people who already have symptoms and are being checked with imaging. If the blood test is positive, you'll get more detailed scans or a biopsy to see if cancer is present.
Ho Chi Minh CityAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT04710758Recruiting
Keyhole surgery for advanced stomach cancer
This trial looks at laparoscopic (keyhole) total stomach removal for people with advanced stomach cancer in the upper or middle part of the stomach. It aims to see whether this operation approach is safe and useful based on your tumor stage and overall health.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06346054Recruiting
Breath and blood test for gastro-esophageal cancer and Barrett's esophagus
This study is testing whether a simple breath and blood test can help doctors better understand gastro-esophageal cancer and Barrett's esophagus. It aims to see if these non-invasive samples can provide useful information for diagnosis and monitoring.
LeuvenAges 18–100 - NCT06340711RecruitingPhase 2
Gene therapy plus Keytruda for advanced stomach or esophageal cancer
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
New York, New YorkAges 18 years+ - NCT06346080Recruiting
Survey on gastro-esophageal cancer screening choices
This study is a survey to understand how patients and the public make choices about screening for gastro-esophageal cancer. It aims to help design better testing programs.
LeuvenAges 18–85 - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT06313801RecruitingPhase 2
Chemotherapy with or without PIPAC for stomach cancer
This trial tests whether adding a special type of chemotherapy sprayed directly into the abdomen (PIPAC) to standard chemotherapy is safer and works better for stomach cancer that has spread only to the lining of the abdomen.
Nizhny NovgorodAges 18–75 - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT06293703Recruiting
Leg length ratio and weight loss after gastric bypass
This study looks at how the length of different parts of your small intestine affects weight loss after Roux-en-Y gastric bypass surgery. It may help doctors tailor the surgery for better results.
Cleveland, OhioAges 18–70 - NCT04809025Recruiting
Testing biopsy samples vs surgery samples for stomach cancer testing
This study compares two ways of getting stomach cancer tissue: a camera-guided biopsy and a tissue sample taken during planned stomach surgery. The goal is to see which sample better supports molecular (gene-based) testing to guide diagnosis.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06266299RecruitingPhase 1
Study of KK2269 for adults with solid tumors
This trial tests a new drug called KK2269 for adults with solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective, possibly as a treatment option for certain cancers like lung or stomach cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
La Jolla, CaliforniaAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT00722228RecruitingPhase 1/Phase 2
Cancer vaccine made from your cells or a donor
This early-phase trial tests a whole-cell cancer vaccine for people with certain metastatic cancers. It aims to help your immune system recognize and fight the cancer, especially when prior chemotherapy hasn’t worked.
JerusalemAges 18 years+ - NCT06222645Recruiting
Comparing two dyes in gastrointestinal surgery
This trial compares two dyes used during stomach or intestine surgery to see which helps surgeons see the blood flow better. It may help decide which dye works best for safe reconnections.
Yantai, ShandongAges 18 years+ - NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Ho Chi Minh City, Hồ Chí MinhAges 18–80
Hear when a new Gastric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric?
- Yes. Clin2 currently lists 850 recruiting gastric studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.